92018-20-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzyloxymethyl)piperazine is utilized as a pharmaceutical agent for its potential therapeutic effects in treating mental health disorders such as psychosis and depression. Its chemical structure allows it to modulate neurotransmitter systems, offering a new avenue for the management of these conditions.
Used in Anticancer Applications:
In the field of oncology, 2-(Benzyloxymethyl)piperazine is employed as a potential anticancer agent, targeting various types of cancer cells. Its mechanism of action may involve the disruption of cellular processes essential for tumor growth and survival, thereby exhibiting potential as a novel therapeutic agent in cancer treatment.
Used in Antiviral Applications:
2-(Benzyloxymethyl)piperazine also serves as an antiviral agent, potentially inhibiting the replication and spread of viruses. Its antiviral properties could be harnessed to develop new treatments for viral infections, offering an alternative or adjunct to existing antiviral therapies.
Used in Drug Synthesis:
As a building block in chemical synthesis, 2-(Benzyloxymethyl)piperazine is used in the creation of various other compounds. Its structural properties make it a valuable component in the development of new drugs, expanding the scope of pharmaceutical research and innovation.

Upstream product

• 1361215-50-0 methyl O-benzyl-L-serylglycinate trifluoroacetate 
• 1361216-93-4 3-(benzyloxymethyl)piperazine-2,5-dione 
• 23680-31-1 BOC-O-benzyl-L-serine 

Downstream Products

• 1361216-92-3 1,1,1-trifluoro-2-(4-(2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-02-8 (2S)-1,1,1-trifluoro-2-(4-((2R)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-00-6 (2R)-1,1,1-trifluoro-2-(4-((2R)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-03-9 (2S)-1,1,1-trifluoro-2-(4-((2S)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-01-7 (2R)-1,1,1-trifluoro-2-(4-((2S)-2-(hydroxymethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361216-95-6 2-(4-(2-((benzyloxy)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-2-propanol 
• 1361217-05-1 (4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl)-2-piperazinyl)methyl methanesulfonate 
• 1361217-89-1 1,1,1-trifluoro-2-(4-(2-((3-pyridinylmethoxy)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-95-9 1,1,1-trifluoro-2-(4-(2-(4-morpholinylmethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361217-45-9 4-(2-thiophenylsulfonyl)-1-(4-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)phenyl)-2-piperazinecarbaldehyde 
• 1361216-94-5 3-(benzyloxymethyl)-1-(thiophen-2-ylsulfonyl)piperazine 

Relevant academic research and scientific papers

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.